Review Article

Effects and Safety of Oral Iron for Heart Failure with Iron Deficiency: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Nannan Tan,1,2,3 Yiqing Cai,1 Junjie Liu,4 Xiaoping Wang,1,2,3 Lin Ma,1,2,3 Guanjing Ling,1,2,3 Jinchi Jiang,1,2,3 Qiyan Wang,2,3,5 and Yong Wang1,2,3

1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2Beijing Key Laboratory of TCM Syndrome and Formula, Beijing, China
3Key Laboratory of Beijing University of Chinese Medicine, Ministry of Education, China
4Department of Cardiology, Nanjing Pukou Hospital of Traditional Chinese Medicine, Nanjing, China
5School of Life Science, Beijing University of Chinese Medicine, Beijing, China

Correspondence should be addressed to Qiyan Wang; wangqiyan2003@126.com and Yong Wang; wangyong@bucm.edu.cn

Received 19 May 2022; Revised 3 July 2022; Accepted 27 July 2022; Published 17 September 2022

Academic Editor: Claudio De Lucia

Copyright © 2022 Nannan Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Oral iron supplement is commonly prescribed to heart failure patients with iron deficiency. However, the effects of oral iron for heart failure remain controversial. This study included randomized controlled trials (RCTs) for meta-analysis to evaluate the effects of oral iron for heart failure patients. Methods. Nine databases (The Cochrane Library, Embase, PubMed, CINAHL, Web of science, CNKI, SinoMed, VIP, and Wanfang) were searched for RCTs of oral iron for heart failure from inception to October 2021. The effects were assessed with a meta-analysis using Revman 5.3 software. The trial sequential analysis was performed by TSA 0.9.5.10 beta software. The risk of bias of trials was evaluated via Risk of Bias tool. The evidence quality was assessed through GRADE tool. Results. Four studies including 582 patients with heart failure and iron deficiency were enrolled. The results indicated that oral iron treatment could improve left ventricular ejection fraction (LVEF, MD = 1.52%, 95% CI: 0.69 to 2.36, \( P = 0.0003 \)) and serum ferritin (MD = 1.64, 95% CI: 0.26 to 3.02, \( P = 0.02 \)). However, there was no between-group difference in the 6-minute walk distances (6MWT), N terminal pro B type natriuretic peptide (NT-proBNP) or hemoglobin level when compared with control group. Subgroup analyses revealed that the effects of oral iron on 6 MWT and serum ferritin could not be affected by duration and frequency of oral iron uptakes. In trial sequential analysis of LVEF and serum ferritin, the Z-curves crossed the traditional boundary and trial sequential monitoring boundary but did not reach the required information size. Conclusion. This analysis showed that oral iron could improve cardiac function measured by LVEF, and iron stores measured serum ferritin, but lack of effect on exercise capacity measured by 6 MWT, and iron stores measured by hemoglobin. Given the overall poor methodological quality and evidence quality, these findings should be treated cautiously.

1. Introduction

Heart failure (HF) is the end stage of a variety of heart diseases that affects approximately 40 million people around the world [1]. It has been reported that the incidence of HF in Europe is about 3/1000 person-years (all age-groups) and the overall incidence is increasing due to the increased aging population [2, 3]. In China, the prevalence of HF among adults aged over 35 is 1.3%, and the mortality rate of inpatients with HF is 4.1% [4, 5]. In the USA, 6 million people are afflicted with HF, and it is estimated that there will be over 8 million people with HF by 2030 [6, 7].

Some studies showed that iron deficiency was a risk factor for HF patients, and approximately 50% of patients with HF had low levels of available iron [8–10]. The pathogenesis of iron deficiency occurring in heart failure is not clear.
Gastrointestinal blood loss, renal failure, and inflammation may be involved [11]. And transferrin and hepcidin are essential serum proteins related to iron metabolism. Transferrin is mainly responsible for the delivery of iron via transferrin-receptor that is a potential biomarker to identify iron deficiency in HF patients [12]. Moreover, high level hepcidin, which is a vital regulator of systemic iron metabolism, can block iron absorption, ultimately leading to iron deficiency [13, 14]. Iron deficiency can cause increased cardiac output, left ventricular hypertrophy, and left ventricular dilation, leading to symptomatic chronic heart failure [11]. Just as Naito et al. indicated that iron-deficient diet could induce anemia, which would eventually lead to left ventricular hypertrophy [15]. Hence, the effects of iron deficiency in HF have gained increased attention in recent years, and iron supplementation is considered as an attractive treatment strategy for HF [16]. Intravenous iron has been becoming prevalent in recent years due to the less toxicity and high efficiency. Ferric carboxymaltose, iron sucrose, iron isomaltoside, sodium ferric gluconate, etc. are common intravenous iron preparations [17]. Several studies indicated that intravenous iron supplementation could improve symptoms, quality of life and length of hospital stay in patients with HF [18–22]. The American College of Cardiology’s 2017 Guidelines for the Prevention of HF demonstrated that the symptoms of HF patients with iron deficiency could be improved by intravenous iron injection [23]. In addition, intravenous iron supplementation with ferric carboxymaltose was recommended for patients with HF in 2021 European Society of Cardiology (ESC) Guidelines and the level of evidence was A [24]. Pezel et al. found that about 39.3% HF patients with iron deficiency received intravenous iron supplementation in French [25]. However, hypophosphatemia and injection reactions at the injection site were observed when patients received intravenous [26, 27].
### Table 1: Characteristic of the included trials.

| Study       | HF diagnosis                                           | Iron deficiency diagnosis                                                                 | Sample size | Age (year) | Gender (male/female) | Intervention                                                                                     | Treatment duration | Outcomes       |
|-------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------|-------------|----------------------|--------------------------------------------------------------------------------------------------|--------------------|----------------|
| Jiang HX    | NYHA through II to III and LVEF <40%                  | Serum ferritin levels <100 μg/L                                                           | 50/50       | 69.12 ± 13.07/69.86 ± 14.74 | 31/19                | Polysaccharide iron complex, 150 mg, once daily                                                 | 24 weeks          | ①②③⑤⑥⑦      |
|             |                                                        |                                            |             |             |                      | Blank control                                                   |                    |                |
| Snezana CZ  | Chronic decompensated HF                               | Serum ferritin levels <100 μg/L and transferrin saturation levels <20%                    | 101/100     | 70.76 ± 9.81/73.3 ± 9.77 | 66/35                | Oral ferric hydroxide polymaltose complex, without ascorbic acid                               | 24 weeks          | ③⑤⑥          |
|             |                                                        |                                            |             |             |                      | Oral ferrous fumarate, ascorbic acid, twice daily                                                       |                    |                |
| Gregory DL  | NYHA through II to IV and LVEF ≤40%                   | Ferritin 15-100 ng/mL or between 100-299 ng/mL with a transferrin saturation below 20%  | 111/114     | 63 (54-71)/63 (55-70) | 67/44                | Polysaccharide iron complex, 150 mg, twice daily                                                | 16 weeks          | ①③⑤⑥         |
|             |                                                        |                                            |             |             |                      | Sugar capsule, 150 mg, twice daily                                                                      |                    |                |
| Wu Y        | NYHA II through IV and LVEF ≤45%                      | Serum ferritin levels <100 ng/mL                                                         | 28/28       | 70 ± 14/70 ± 10 | 28/8                 | Polysaccharide iron complex, 150 mg, once daily                                                 | 18 weeks          | ②③⑤          |
|             |                                                        |                                            |             |             |                      | Intravenous sucrose iron                                                                                    |                    |                |

NYHA: New York Heart Association classification; LVEF: left ventricular ejection fraction; NT-proBNP; LVEF; 6-minute walk distance; hemoglobin; serum ferritin; quality of life; adverse event.
In addition to intravenous iron injection, oral iron is frequently prescribed to patients with iron deficiency [28]. Ferrous sulfate, ferrous gluconate, and ferrous fumarate are common preparations in clinical [29]. The HF patients received oral iron supplementation even more frequent than intravenous supplementation [30]. However, it is not recommended in HF guidelines. There may be several reasons. Firstly, oral iron supplementation is not as effective as intravenous iron supplementation in HF patients with iron deficiency [31]. Secondly, intestinal functions are usually compromised in patients with HF due to inadequate oxygen supply and this will affect iron absorption [32]. Lewis et al. suggested that oral iron supplementation could not significantly improve exercise ability in HF patients with reduced ejection fraction and is therefore not useful for HF patients [33]. However, other studies suggested that oral iron may be beneficial for HF patients [34, 35]. The results of randomized controlled trials (RCTs) were inconsistent and the evidence was inadequate [36]. Hence, the efficiency of oral iron in the treatment of HF awaits further investigations [37].

In this study, we performed a systematic review and meta-analysis of RCTs to assess the effects and safety of oral iron in the treatment of HF patients with iron deficiency. In addition, we explored whether the effects were influenced by the frequency and duration of oral iron uptakes.

2. Methods

2.1. Registration. The protocol of this systematic review and meta-analysis was registered on PROSPERO under the number CRD42021282982.
2.2. Search Strategy. The Cochrane Library, Embase, Pubmed, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Service System (SinoMed), Chinese Scientific Journals (VIP) Database, and Wanfang Data Chinese database (Wanfang) were searched by two authors independently from inception to October 2021. English search terms included: heart failure, cardiac failure, congestive heart, myocardial failure, heart decompensation, iron, iron compounds, ferric, ferrous, and iron deficiency. Chinese search terms included: xin_li_shuai_jie, xin_shuai, tie, ya_tie, er_jia_tie, san_jia_tie, tie_ji, and tie_que_fa. Only RCTs published in English or Chinese language were included. Taking PubMed as an example, specific search strategies were shown in Figure 1.

2.3. Inclusion and Exclusion Criteria. According to 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF [24], RCTs that enrolled HF patients (no type of restriction) with ejection fraction threshold <50% and serum ferritin lower than 100 ng/mL or serum ferritin 100-299 ng/mL with transferrin saturation (TSAT) <20% were included. The intervention included oral iron only, regardless of treatment duration. The comparisons included usual care, placebo, or other comparators, regardless of treatment duration. The primary outcomes were left ventricular ejection fraction (LVEF), 6-minute walk distances (6 MWT), and serum ferritin. The secondary outcomes were N terminal pro B type natriuretic peptide (NT-proBNP), hemoglobin, the quality of life, safety, and adverse events.

Studies with the following conditions were excluded: (1) duplicate articles and (2) articles where data reports were incomplete, or data were not available.

2.4. Study Selection and Data Extraction. After deleting duplicate literature, two reviewers screened the titles and abstracts independently by using Endnote X9 software. Studies relevant to the purpose of this review were included to read the full texts. Reference lists of relevant studies were also reviewed to supplement the missing studies. Discrepancies were resolved by a third reviewer. The selection procedure was shown in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart.

The following information from the included studies was extracted: first author, year of publication, the diagnosis of

| Study or subgroup | Mean E | SD Total | Mean C | SD Total | Weight Mean difference | IV, fixed, 95% CI | Mean difference | IV, fixed, 95% CI |
|-------------------|---------|----------|--------|----------|------------------------|------------------|--------------------|------------------|
| Jiang Hexi 2020   | 4.19    | 2.21    | 62     | 2.55     | 2.30937221 50 88.8%    | 1.64 [0.75, 2.53] |                    |                  |
| Snezana Ciric Zdravkovic 2019 | 0.17  | 10.5511 | 101    | -0.1     | 13.78386 100 6.1%      | 0.27 [-3.13, 3.67] |                    |                  |
| Wu Yun 2013       | 8       | 5.56    | 70     | 7        | 8.185333 28 5.2%       | 1.00 [-2.67, 4.67] |                    |                  |
| Total (95% CI)    | 179     | 178     | 100.0% | 100      | 1.52 [0.69, 2.36]      |                  |                    |                  |

Heterogeneity: Chi² = 0.67, df = 2 (P = 0.72); I² = 0%
Test for overall effect: Z = 3.58 (P = 0.0003)

(a) Forest plots of the effect of oral iron on LVEF; (b) trial sequential analysis of LVEF.

Figure 4: (a) Forest plots of the effect of oral iron on LVEF; (b) trial sequential analysis of LVEF.
### Figure 5: Continued.
HF and iron deficiency, sample size, characteristic of participants (age, gender), intervention, treatment duration, and outcomes. Data extraction was performed by two reviewers independently.

2.5. Quality Assessment

2.5.1. Risk of Bias. The assessment of risk of bias for RCTs was performed independently by two authors using the Risk of Bias (RoB) tool mentioned in Cochrane Handbook for Systematic Reviews of Interventions [38]. Selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessors), attrition bias, reporting bias, and other sources of bias were assessed. In accordance with the RoB, for each bias judgement could be “low risk”, “high risk”, or “unclear risk”.

2.5.2. Quality of Evidence. The quality of evidence was estimated by the standard Grading of Recommendation Assessment, Development and Evaluation (GRADE) tool. Five domains were assessed by two researchers, including (1) risk of bias; (2) inconsistency in the results; (3) indirectness of evidence; (4) imprecision of evidence; (5) publication bias. One domain with a serious problem can degrade the quality by one level, when there is a very serious problem with the domain, this can reduce the quality by two levels. The quality of evidence for outcomes could be rated into four levels: very low, low, moderate, or high using this standard approach [39].

2.6. Statistical Analysis. Data analysis was performed using RevMan 5.3 software. Continuous variables were presented as mean difference (MD) or standard mean difference (SMD), with 95% confidence intervals (CI). P < 0.05 was defined as statistically significant. The $I^2$ test and $\chi^2$ test were conducted to quantify the statistical heterogeneity between trials. A fixed-effects model was used when $P \geq 0.1$ and $I^2 < 50\%$ and the PICO’s of the trials in the meta-analysis had no obvious clinical diversity, while a random-effects model was used when $P < 0.1$ or $I^2 \geq 50\%$. The one-study-omission sensitivity analysis was conducted to determine the possible source of heterogeneity. Subgroup analyses based on treatment durations and frequency of oral iron were performed to explore the possible dose response relationship between the intervention characteristics and changes in outcomes when sufficient trials were included. The trial sequential analysis (TSA) was performed by TSA 0.9.5.10 beta software to verify the stability of the results and to estimate the total sample size required for meta-analysis. Publication bias was analyzed by funnel plot when at least 10 trials were included in a meta-analysis.

3. Results

3.1. Study Identification and Characteristic. The original search retrieved 3214 eligible studies. 1346 duplicated studies were excluded. Further screening excluded 1844 studies based on titles and abstracts, and 24 studies were selected.
Four studies [33, 40–42] were included after the full texts were reviewed. The data retrieving process was shown in Figure 2. The four studies enrolled 582 patients, assigned to oral iron group (n = 290) versus control group (n = 292). One study was taken place in the United States, one in Serbia, and two in China. The specific information was shown in Table 1.

3.2. Risk of Bias Assessment. We identified the high overall risk of bias for all trials because at least one domain in each of these trials was judged to be at unclear or high risk of bias. As shown in Figures 3(a) and 3(b), one trial (25%) did not provide the method of random sequence generation and three trials (75%) did not report the method of allocation concealment. Therefore, they were assessed as having unclear risk of selection bias. The performance bias was rated as unclear risk because two trials (50%) did not mention the information about binding of participants and personnel, and the detection bias was unclear risk because two trials (50%) did not report the information about binding of outcome assessment. One trial (25%) did not provide the information about incomplete outcome data, and one trial (25%) mentioned one case of loss to follow-up, indicating that there was attrition bias. Reporting bias was detected in one trial (25%) because the results of some outcomes included were not reported.

3.3. Primary Outcome

3.3.1. LVEF. Three RCTs (with 357 patients) reported the effects of oral iron on LVEF. The meta-analysis with a fixed-effects model showed that the LVEF was improved by oral iron administration (MD = 1.52%, 95% CI: 0.69 to 2.36, P = 0.0003, I² = 0%, Figure 4(a)). The result of the TSA on LVEF showed that the cumulative Z-curves crossed both the conventional boundary and the trial sequential monitoring boundary, indicating the reliability of the meta-analysis result that support the benefit of oral iron for HF. However, the cumulative sample size did not reach the required information size of 417. As shown in Figure 4(b).

3.3.2. 6-Minute Walk Distances. The result of meta-analysis of 4 RCTs (582 patients) with a random-effects model...

---

**Figure 6:** Sensitivity analysis of 6-minute walk distances.
| Study or subgroup | Experimental Mean | Experimental SD | Control Mean | Control SD | Total | Weight | Std. mean difference IV, random, 95% CI | Mean difference IV, random, 95% CI |
|------------------|------------------|----------------|--------------|-----------|-------|--------|---------------------------------|-----------------------------|
| 12.1.1 Once a week |                 |                 |              |           |       |        |                                 |                             |
| Jiang Hexi 2020  | 4.52             | 8.921345        | 50           | 7.8       | 8.732119 | 50     | 25.3% [0.81, 52.32] [48.86, 55.78] |                             |
| Wu Yun 2013      | 15               | 20.42058        | 28           | 11        | 20.07486 | 28     | 24.5% [4.00, 14.61] [−6.61, 14.61] |                             |
| Subtotal (95% CI)| 78               | 49.8%           |              |           |        |        | 28.43 [−5.14, 21.87] |                             |
| Heterogeneity: Tau^2 = 1.151; Chi^2 = 62.06, df = 1 (P < 0.00001); I^2 = 99% |
| Test for overall effect: Z = 1.21 (P = 0.22) |
| Total (95% CI)   | 290              | 100.0%          |              |           |        |        | 18.31 [−5.14, 21.87] |                             |
| Heterogeneity: Tau^2 = 1.751; Chi^2 = 79.55, df = 3 (P < 0.00001); I^2 = 99% |
| Test for overall effect: Z = 1.05 (P = 0.29) |
| Test for subgroup differences: Chi^2 = 2.64, df = 1 (P = 0.43); I^2 = 99% |

| Study or subgroup | Experimental Mean | Experimental SD | Control Mean | Control SD | Total | Weight | Std. mean difference IV, random, 95% CI | Mean difference IV, random, 95% CI |
|------------------|------------------|----------------|--------------|-----------|-------|--------|---------------------------------|-----------------------------|
| 12.1.2 Twice a week |                 |                 |              |           |       |        |                                 |                             |
| Gregory D. Lewis 2017 | 20.1778517641 | 111             | 5            | 18.9291442 | 114   | 25.2% | 15.00 [10.20, 19.80] |                             |
| Snezana Ciric Zdravkovic 2019 | 29.32 | 27.99058 | 101          | 28.11     | 23.13586 | 100   | 25.0% | 1.21 [−5.89, 8.31] |                             |
| Subtotal (95% CI) | 212              | 50.2%           |              |           |        |        | 8.36 [−5.14, 21.87] |                             |
| Heterogeneity: Tau^2 = 8.553; Chi^2 = 9.55, df = 1 (P = 0.002); I^2 = 90% |
| Test for overall effect: Z = 1.21 (P = 0.22) |
| Total (95% CI)   | 290              | 100.0%          |              |           |        |        | 18.31 [−8.79, 45.41] |                             |
| Heterogeneity: Tau^2 = 7.511; Chi^2 = 279.55, df = 3 (P < 0.00001); I^2 = 99% |
| Test for overall effect: Z = 1.05 (P = 0.29) |
| Test for subgroup differences: Chi^2 = 2.64, df = 1 (P = 0.43); I^2 = 99% |

Figure 7: Continued.
illustrated that there was no significant effect of oral iron on 6 MWT (MD = −13.92 m, 95% CI: -47.33 to 19.50, \( P = 0.41 \), \( I^2 = 90\% \), Figure 5(a)). Sensitivity analysis showed that when the study of Jiang Hexi was removed, the \( I^2 \) decreased to 0\%, as shown in Figure 6.

Due to the availability of the number of trials, subgroup analyses were performed on 6 MWT. The subgroup analysis based on treatment frequency showed that taking oral iron either once a day (MD = 7.77, 95% CI: -26.55 to 41.94, \( P = 0.66 \), \( I^2 = 62\% \)) or twice a day (MD = -35.19, 95% CI: -44.59 to -25.79, \( P < 0.0001 \), \( I^2 = 0\% \)) had no difference of effect on 6 MWT (Figure 5(b)). In the subgroup of treatment duration, oral iron treatment lasting less 6 months (MD = −34.80, 95% CI: -44.36 to -25.25, \( P < 0.0001 \), \( I^2 = 0\% \)) or over 6 months (MD = −13.92, 95% CI: -47.33 to 19.50, \( P = 0.97 \), \( I^2 = 85\% \)) could not improve 6 MWT in HF patients with iron deficiency (Figure 5(c)).

The result of the TSA on 6 MWT showed that the cumulative Z-curves did not cross both the conventional boundary and the trial sequential monitoring boundary, indicating no potential advantages for oral iron on 6 MWT. However, the cumulative sample size did not reach the required information size of 2056 (Figure 5(d)).

### 3.3.3. Serum Ferritin

The result of meta-analysis of 4 RCTs (582 patients) with a random-effects model showed that oral iron could improve serum ferritin level (MD = 1.64, 95% CI: -0.26 to 3.02, \( P = 0.02 \), \( I^2 = 98\% \), Figure 7(a)). Sensitivity analysis showed that the heterogeneity was not obviously decreased when four studies were removed one by one, as shown in Figure 8.

The subgroup analyses of treatment frequency and duration on serum ferritin illustrated that no dose-response relationships were identified between the frequency of oral iron and changes in serum ferritin (Figures 7(b) and 7(c)).

The result of the TSA on serum ferritin showed that the cumulative Z-curves crossed both the conventional boundary and the trial sequential monitoring boundary, indicating the reliability of the meta-analysis results that support the benefits of oral iron for HF patients. However, the cumulative sample size did not reach the required information size of 686. As shown in Figure 7(d).

### 3.4. Secondary Outcomes

#### 3.4.1. Hemoglobin

The result of meta-analysis of 2 RCTs (257 patients) with a random-effects model reported that oral iron had no effect on hemoglobin (SMD = -0.45, 95% CI: -0.92 to 0.03, \( P = 0.06 \), \( I^2 = 61\% \), Figure 9).

#### 3.4.2. NT-proBNP

The result of meta-analysis of 2 RCTs (325 patients) with a random-effects model showed that the level of NT-proBNP was not reduced by oral iron (MD = -380.74 pg/mL, 95% CI: -994.83 to 183.34, \( P = 0.19 \), \( I^2 = 96\% \), Figure 10).

### 3.5. Quality of Life

Two studies reported the quality of life. Lewis et al. used the Kansas City Cardiomyopathy (KCCQ) to estimate the quality of life in patients with HF. The result showed that oral iron could not improve quality of life scores at the end of 16 weeks. However, the study by Jiang Hexi revealed that oral iron was beneficial for the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores at the end of 24 weeks, not 16 weeks.
3.6. Safety of Oral Iron. Three studies reported adverse events. The RCT by Snezana Ciric Zdravkovic reported that patients taking ferric supplements had sporadic intolerance, but no patients stopped taking iron supplements during the experiment. The study by Jiang Hexi found that mild nausea occurred in oral iron group, but none of the patients quit the study either. Lewis et al. found that the adverse events were similar between oral iron and placebo group. Overall, the adverse events of oral iron seemed to be mild and tolerable.

3.7. Publication Bias. The publication bias was not analyzed because the number of RCTs reported each outcome was less than 10.

3.8. Quality of Evidence. The evidence quality of the effects of oral iron on LVEF and 6 MWT was low, and the evidence quality on NT-proBNP, serum ferritin, and hemoglobin were very low (Table 2).
The main findings of this systematic review and meta-analysis indicated that oral iron could improve cardiac function measured by LVEF and iron stores measured by serum ferritin, but lack of effect on exercise capacity measured by 6 MWT and iron stores measured by hemoglobin. And there were no dose-response relationships between the frequency and duration of oral iron and changes in 6MWT and serum ferritin.

6 MWT, NT-proBNP, and hemoglobin were not improved by oral iron in our study. However, oral iron supplementation could improve LVEF and serum ferritin. TSA can compensate for the risk of random errors producing in traditional meta-analysis and estimate the required amount of information and the stability of the result of meta-analysis. Moreover, the false positive result can be prevented effectively. In our study, the results of TSA on LVEF and serum ferritin supported the benefits of oral iron for HF patients in meta-analysis, but not reached the required information size, further investigations were needed to support the stability of result. Considering the high heterogeneity of serum ferritin and the possible source was not tracked, the result of serum ferritin should be treated with caution. The sensitivity analysis of 6 MWT showed that when the study of Jiang Hexi was removed, the heterogeneity became lower. The study might be the source of high heterogeneity.

The subgroup analysis showed that no dose-response relationships were identified between the frequency and duration of oral iron and changes on 6 MWT and serum ferritin. However, some studies have shown that daily take of low dose of iron supplementation was better than high dose for treating anemia in pregnant patients, and alternate day was better than daily iron supplementation [26, 43]. The study by Moretti et al. had similar conclusion [44]. Hence, we still suggest that the effect of different dose and duration of oral iron require further research although our result is negative.

Iron is vital for numerous biological processes. The heart is more susceptible to iron deficiency because iron is a metal cofactor participating in the formation of mitochondrial enzymes that support the high energy requirements of myocardial contraction [45–47]. Fatigue, poor physical performance and decreased exercise tolerance has been observed in HF patients with iron deficiency [48]. Iron supplement, especially intravenous products, is beneficial to improve 6 MWT, peak oxygen consumption, and quality of life [9]. HF patients with iron deficiency, regardless the anemia status, intravenous iron therapy should be considered [36]. In addition to intravenous iron supplement, oral iron is often prescribed to HF patients with iron deficiency. Pezel et al. found that 40 of 168 HF patients received oral iron treatment in French [25]. And more than 90% patients received oral treatment in four Europe countries [49]. However, the effects of oral iron for HF patients with iron deficiency are still controversial. The poor absorption of oral iron may affect the effects for HF patients with iron deficiency. Firstly, drugs such as proton pump inhibitors (PPIs) and histamine H2 receptor antagonist (H2RA) which have potential effectiveness in treating HF can interfere the absorption of iron [50, 51]. Secondly, patients with HF may develop intestinal edema after venous congestion due to increased pressure in the right atrium [52]. The cardiac output, systemic circulating blood flow, and intestinal wall barrier may decrease during heart failure [32, 53]. Intestinal function should be taken into consideration when prescribing oral iron to HF patients [54]. In addition, iron absorption is reduced due to inflammation which is involved in the pathogenesis and progression of HF [28, 55]. According to the findings of this meta-analysis, although oral iron is beneficial to LVEF and serum ferritin, more evidence for oral iron preparations in HF patients is still needed.

This study had some limitations. Firstly, we only included studies of HF patients with LVEF <50% and the extensibility of conclusions is limited. Secondly, we focused mainly on surrogate endpoints and did not include key patient-oriented outcomes such as HF hospitalization, and death. Thirdly, there was a lack of high quality RCTs of oral iron on heart failure and the number of enrolled studies was relatively small. Fourthly, we could not conduct separate meta-analysis based on different comparisons, i.e., placebo or blank control, because the number of included studies is insufficient. Finally, the publication bias was not analyzed because the number of each outcome was less than 10.

| Study or subgroup | Experimental Mean | Experimental SD | Total Mean | Control Mean | Control SD | Total Weight | Mean difference IV, random, 95% CI | Mean difference IV, random, 95% CI |
|------------------|------------------|----------------|------------|--------------|------------|--------------|----------------------------------|----------------------------------|
| Gregory D. Lewis 2017 | -183 484.493885 | 111 | -85 | 518.0389102 | 114 | 50.9% | -98.00 [-229.02, 33.02] |  |
| Jiang Hexi 2020 | -1,809.7 268.5754 | 50 | -1,136 | 667.3611 | 50 | 49.1% | -673.70 [-873.10, -474.30] |  |

Total (95% CI) 161 164 100.0% -380.74 [-944.83, 183.34]  
Heterogeneity: Tau^2 = 158305.81; Chi^2 = 22.37, df = 1 (P < 0.00001); I^2 = 96%
Test for overall effect: Z = 1.32 (P = 0.19)
| Outcomes   | Risk of bias | Inconsistency | Indirectness | Imprecisions | Publication bias | Quality result |
|------------|--------------|---------------|--------------|--------------|-----------------|----------------|
| LVEF       | Serious limitation<sup>a</sup> | No serious limitation | No serious limitation | Serious limitation<sup>e</sup> | Not detected | Low            |
| NT-proBNP  | Serious limitation<sup>a</sup> | Very serious limitation<sup>d</sup> | No serious limitation | Serious limitation<sup>e</sup> | Not detected | Very low       |
| 6MWT       | Serious limitation<sup>a</sup> | No serious limitation | No serious limitation | Serious limitation<sup>e</sup> | Not detected | Low            |
| Serum ferritin | Very serious limitation<sup>b</sup> | Very serious limitation<sup>d</sup> | No serious limitation | No serious limitation | Not detected | Very low       |
| Hemoglobin | Very serious limitation<sup>b</sup> | Serious limitation<sup>c</sup> | No serious limitation | Serious limitation<sup>e</sup> | Detected<sup>f</sup> | Very low       |

LVEF: left ventricular ejection fraction; NT-proBNP: N terminal pro B type natriuretic peptide; 6MWT: 6-minute walk distance; <sup>a</sup>: most information is from trials at unclear risk of bias, which has serious limitations, that raises some doubt about the results; <sup>b</sup>: most information is from trials at high risk of bias, which has very serious limitations, that seriously weakens confidence in the results; <sup>c</sup>: represents heterogeneity ($I^2>50\%$), with treating or interpreting by subgroup analysis or sensitivity analysis, but heterogeneity remained 50%-75%; <sup>d</sup>: represents heterogeneity ($I^2>75\%$), with treating or interpreting by subgroup analysis or sensitivity analysis, but heterogeneity remained >75%; <sup>e</sup>: results without clinical significance or small sample sizes (<400); <sup>f</sup>: publication bias may exist when these small sized studies with all the positive or negative results.
5. Conclusion

Oral iron could improve cardiac function measured by LVEF, and iron stores measured by serum ferritin, but lack of effect on exercise capacity measured by 6 MWT, and iron stores measured by hemoglobin. Given the overall poor methodological quality and evidence quality, these findings should be treated cautiously. More high-quality RCTs are needed in the future.

Data Availability

Data would be available pending the request from corresponding authors.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Nannan Tan, Yiqing Cai, and Junjie Liu equally contributed for the conception and design. Yong Wang and Qian Wang were responsible for the administrative support. Junjie Liu and Xiaoping Wang were responsible for the provision of study materials or patients. Yiqing Cai and Lin Ma were responsible for the collection and assembly of data. Nannan Tan and Yiqing Cai were responsible for the data analysis and interpretation. All authors contributed in manuscript writing and approved of the manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number 81822049).

References

[1] J. R. Baman and F. S. Ahmad, “Heart failure,” *Heart Failure Juna*, vol. 324, no. 10, p. 1015, 2020.
[2] N. Conrad, A. Judge, J. Tran et al., “Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals,” *The Lancet*, vol. 391, no. 10120, pp. 572–580, 2018.
[3] S. Meyer, F. P. Brouwers, A. A. Voors et al., “Sex differences in new-onset heart failure,” *Clinical Research in Cardiology: Official Journal of the German Cardiac Society*, vol. 104, no. 4, pp. 342–350, 2015.
[4] Y. Zhang, J. Zhang, J. Butler et al., “Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry,” *Journal of Cardiac Failure*, vol. 23, no. 12, pp. 868–875, 2017.
[5] G. Hao, X. Wang, Z. Chen et al., “Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015,” *European Journal of Heart Failure*, vol. 21, no. 11, pp. 1329–1337, 2019.
[6] P. A. Heidenreich, N. M. Albert, L. A. Allen et al., “Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association,” *Circulation: Heart Failure*, vol. 6, no. 3, pp. 606–619, 2013.
[7] S. S. Virani, A. Alonso, H. J. Aparicio et al., “Heart disease and stroke statistics-2021 update: a report from the American Heart Association,” *Circulation*, vol. 143, no. 8, pp. e254–e743, 2021.
[8] I. S. Anand and P. Gupta, “Anemia and iron deficiency in heart failure,” *Circulation*, vol. 138, no. 1, pp. 80–98, 2018.
[9] S. von Haehling, N. Ebner, R. Evertz, P. Ponikowski, and S. D. Anker, “Iron deficiency in heart failure: an overview,” *JACC Heart Failure*, vol. 7, no. 1, pp. 36–46, 2019.
[10] E. A. Jankowska, P. Rozentryt, A. Witkowska et al., “Iron deficiency: an ominous sign in patients with systolic chronic heart failure,” *European Heart Journal*, vol. 31, no. 15, pp. 1872–1880, 2010.
[11] E. A. Jankowska and P. Ponikowski, “Molecular changes in myocardium in the course of anemia or iron deficiency,” *Heart Failure Clinics*, vol. 6, no. 3, pp. 295–304, 2010.
[12] R. Sierpinski, K. Josiak, T. Suchocki et al., “High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality,” *European Journal of Heart Failure*, vol. 23, no. 6, pp. 919–932, 2021.
[13] D. Girelli, E. Nemeth, and D. W. Swinkels, “Hepcidin in the diagnosis of iron disorders,” *Blood*, vol. 127, no. 23, pp. 2809–2813, 2016.
[14] P. Cacoub, G. Choukroun, A. Cohen-Solal et al., “Iron deficiency screening is a key issue in chronic inflammatory diseases: a call to action,” *Journal of Internal Medicine*, 2022.
[15] Y. Naito, T. Tsujino, M. Matsumoto, T. Sakoda, M. Ohyanagi, and T. Masuyama, “Adaptive response of the heart to long-term anemia induced by iron deficiency,” *American Journal of Physiology Heart and Circulatory Physiology*, vol. 296, no. 3, pp. H585–H593, 2009.
[16] E. A. Jankowska, S. von Haehling, S. D. Anker, I. C. Macdougall, and P. Ponikowski, “Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives,” *European Heart Journal*, vol. 34, no. 11, pp. 816–829, 2013.
[17] M. Auerbach, A. Gafter-Gvili, and I. C. Macdougall, “Intravenous iron: a framework for changing the management of iron deficiency,” *The Lancet Haematology*, vol. 7, no. 4, pp. e342–e350, 2020.
[18] G. Charles-Edwards, N. Amaral, A. Sleigh et al., “Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency,” *Circulation*, vol. 139, no. 21, pp. 2386–2398, 2019.
[19] P. Ponikowski, B. A. Kirwan, S. D. Anker et al., “Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial,” *Lancet (London, England)*, vol. 396, no. 10266, pp. 1895–1904, 2020.
[20] P. Ponikowski, D. J. van Veldhuisen, J. Comin-Colet et al., “Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency,” *European Heart Journal*, vol. 36, no. 11, pp. 657–668, 2015.
[21] S. D. Anker, J. Comin-Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” *The New England Journal of Medicine*, vol. 361, no. 25, pp. 2436–2448, 2009.
[22] D. J. van Veldhuisen, P. Ponikowski, P. van der Meer et al., “Effect of ferric carboxymaltose on exercise capacity in
patients with chronic heart failure and iron deficiency,” Circulation, vol. 136, no. 15, pp. 1374–1383, 2017.

[23] C. W. Yancy, M. Jessup, B. Bozkurt et al., “2017 ACC/AHA/HFSA focused update of the 2013 ACC/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America,” Circulation, vol. 136, no. 6, pp. e137–e161, 2017.

[24] T. A. McDonagh, M. Metra, M. Adamo et al., “Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC,” European Heart Journal, vol. 42, no. 48, p. 4901, 2021.

[25] T. Pezel, E. Audureau, J. Mansourati et al., “Diagnosis and treatment of iron deficiency in heart failure: OFICSE study by the French heart failure working group,” ESC Heart Failure, vol. 8, no. 2, pp. 1509–1521, 2021.

[26] L. Reveiz, G. M. Gyte, L. G. Cuervo, and A. Casabuenas, “Treatments for iron-deficiency anaemia in pregnancy,” The Cochrane Database of Systematic Reviews, 2011.

[27] E. Ifie, S. O. Oyibo, H. Joshi, and O. Akintade, “Symptomatic hypophosphatemia after intravenous iron therapy: an under-rated adverse reaction,” Endocrinology, Diabetes & Metabolism Case Reports, vol. 2019, no. 1, 2019.

[28] S. R. Pasricha, J. Tye-Din, M. U. Muckenthaler, and D. W. Swinkels, “Iron deficiency,” The Lancet (London, England), vol. 397, no. 10270, pp. 233–248, 2021.

[29] S. Rizvi and R. E. Schoen, “Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap?,” The American Journal of Gastroenterology, vol. 106, no. 11, pp. 1872–1879, 2011.

[30] A. Cohen-Solal, T. Damy, M. Terbah et al., “High prevalence of iron deficiency in patients with acute decompensated heart failure,” European Journal of Heart Failure, vol. 16, no. 9, pp. 984–991, 2014.

[31] E. Sciatti, U. Nesti, and A. Di Lenarda, “Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis,” Monaldi Archives for Chest Disease = Archivio Monaldi per le Malattie del Torace, vol. 91, no. 3, 2021.

[32] A. Sandek, J. Bauditz, A. Swidzinski et al., “Altered intestinal function in patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 50, no. 16, pp. 1561–1569, 2007.

[33] G. D. Lewis, R. Malhotra, A. F. Hernandez et al., “Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency,” The IRONOUT HF randomized clinical trial Journal of the American Medical Association, vol. 317, no. 19, pp. 1958–1966, 2017.

[34] E. D. Niehaus, R. Malhotra, D. Coca-Spoftord, M. Semigran, and G. D. Lewis, “Repletion of iron stores with the use of oral iron supplementation in patients with systolic heart failure,” Journal of Cardiac Failure, vol. 21, no. 8, pp. 694–697, 2015.

[35] A. Karavidas, E. Troganis, G. Lazaros et al., “Oral succosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study,” European Journal of Heart Failure, vol. 23, no. 4, pp. 593–597, 2021.

[36] T. McDonagh and I. C. Macdougall, “Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?,” European Journal of Heart Failure, vol. 17, no. 3, pp. 248–262, 2015.

[37] G. D. Lewis, M. J. Semigran, M. M. Givertz et al., “Oral iron therapy for heart failure with reduced ejection fraction,” Heart Failure, vol. 9, no. 5, 2016.

[38] J. P. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, and V. A. Welch, Eds., Cochrane handbook for systematic reviews of interventions, John Wiley & Sons, 2019.

[39] Y. Cai, X. Liu, A. Zhao et al., “Effects of tai chi on health outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis,” Journal of Traditional Chinese Medical Sciences, vol. 9, no. 2, pp. 108–120, 2022.

[40] S. C. Zdravkovic, S. P. Nagorni, I. Cokbasic et al., “Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure,” The Journal of International Medical Research, vol. 47, no. 7, pp. 3179–3189, 2019.

[41] H. M. Wu Yun, G. Batola, A. Aierken, and M. Hujiaihemaiti, “Effect of iron supplementation on chronic heart failure with iron deficiency anemia,” Guangdong Medicine, vol. 2, pp. 302–304, 2013.

[42] Z. Y. Jiang Hexi, “Oral iron heart function in patients with chronic heart failure with iron deficiency and the influence of the quality of life,” Journal of Jinzhou Medical College Journal, vol. 9, no. 5, pp. 105–108, 2020.

[43] N. U. Stoffel, C. I. Cerramondi, G. Brittenham et al., “Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials,” The Lancet Haematology, vol. 4, no. 11, pp. e524–e533, 2017.

[44] D. Moretti, J. S. Goede, C. Zeder et al., “Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women,” Blood, vol. 126, no. 17, pp. 1981–1989, 2015.

[45] N. C. Andrews, “Disorders of iron metabolism,” The New England Journal of Medicine, vol. 341, no. 26, pp. 1986–1995, 1999.

[46] A. N. Carley, H. Taegtmeyer, and E. D. Lewandowski, “Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart,” Circulation Research, vol. 114, no. 4, pp. 717–729, 2014.

[47] V. Melenovsky, J. Petrak, T. Mracek et al., “Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis,” European Journal of Heart Failure, vol. 19, no. 4, pp. 522–530, 2017.

[48] M. D. Cappellini, K. M. Musallam, and A. T. Taher, “Iron deficiency anaemia revisited,” Journal of Internal Medicine, vol. 287, no. 2, pp. 153–170, 2020.

[49] C. F. F. Mor, P. Vasko, M. Frick, and D. Mitchell, “Diagnosis and treatment of iron deficiency and anemia in chronic heart failure: current practice in four European countries,” Circulation, vol. 2011, no. 124, article A14991, 2011.

[50] J. R. Lam, J. L. Schneider, C. P. Quesenberry, and D. A. Corley, “Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency,” Gastroenterology, vol. 152, no. 4, pp. 821, 2017.

[51] K. Adelborg, J. Sandstill, M. Schmidt et al., “Use of histamine H2 receptor antagonists and outcomes in patients with heart
failure: a nationwide population-based cohort study,” Clinical Epidemiology, vol. Volume 10, pp. 521–530, 2018.

[52] M. Valentova, S. von Haehling, J. Bauditz et al., “Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure,” European Heart Journal, vol. 37, no. 21, pp. 1684–1691, 2016.

[53] W. H. W. Tang, D. Y. Li, and S. L. Hazen, “Dietary metabolism, the gut microbiome, and heart failure,” Nature Reviews Cardiology, vol. 16, no. 3, pp. 137–154, 2019.

[54] T. G. DeLoughery, “Safety of oral and intravenous iron,” Acta Haematologica, vol. 142, no. 1, pp. 8–12, 2019.

[55] Y. Zhang, J. Bauersachs, and H. F. Langer, ”Immune mechanisms in heart failure,” European Journal of Heart Failure, vol. 19, no. 11, pp. 1379–1389, 2017.